Publications by authors named "Samuel Agresta"

Claim this Profile
A
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies.
Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, Kapil N Bhalla, Alfonso Quintás-Cardama, Samuel Agresta

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik, Samuel Agresta

Clin Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Bin Fan, David Dai, Courtney D DiNardo, Eytan Stein, Stéphane de Botton, Samuel V Agresta

Cancer Chemother Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Gail J Roboz, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Alice S Mims, Samuel V Agresta

Blood· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Daniel A Pollyea, Martin S Tallman, Stéphane de Botton, Hagop M Kantarjian, Robert Collins, Samuel V Agresta

Leukemia· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Maeve A Lowery, Howard A Burris, Filip Janku, Rachna T Shroff, James M Cleary, Samuel V Agresta

Lancet Gastroenterol Hepatol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
David Dai, Hua Yang, Salah Nabhan, Hua Liu, Denice Hickman, Samuel Agresta

Eur J Clin Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model.
Fang Wang, Jeremy Travins, Zhizhong Lin, Yaguang Si, Yue Chen, Samuel Agresta

J Inherit Metab Dis· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
Courtney D DiNardo, Kathleen J Propert, Alison W Loren, Elisabeth Paietta, Zhuoxin Sun, Samuel Agresta

Blood· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Amir T Fathi, Hossein Sadrzadeh, Darrell R Borger, Karen K Ballen, Philip C Amrein, Samuel Agresta

Blood· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Joseph G Reynolds, Elena Geretti, Bart S Hendriks, Helen Lee, Shannon C Leonard, Samuel V Agresta

Toxicol Appl Pharmacol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Manish Gupta, Patricia M Lorusso, Bei Wang, Joo-Hee Yi, Howard A Burris, Samuel Agresta

J Clin Pharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
S Tariq Mahmood, Samuel Agresta, Carlos E Vigil, Xiuhua Zhao, Gang Han

Int J Cancer· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical issues of intraoperative frozen section diagnosis of bone and soft tissue lesions.
Marilyn M Bui, Prudence Smith, Samuel V Agresta, David Cheong, G Douglas Letson

Cancer Control· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.
Audrey C Shor, Samuel V Agresta, Gina Z D'Amato, Vernon K Sondak

Cancer Control· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current issues in adolescent and young adult cancer survivorship.
Hatem Soliman, Samuel V Agresta

Cancer Control· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rhabdomyosarcoma of the maxillary gingiva.
Angela C Chi, Jeffrey D Barnes, Steven Budnick, Samuel V Agresta, Brad Neville

J Periodontol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis